D elirium, characterized by an acute onset and fluctuating course of inattention and either disorganized thinking or an altered level of consciousness, is reported in 50% of cardiac surgical patients 1 and is associated with increased length of intensive care unit (ICU) stay, morbidity, mortality, and long-term cognitive decline. 2, 3 Risk factors such as preexisting cognitive dysfunction, postoperative pain, use of opioids and sedatives, and surgical inflammation have been associated with delirium. 2, 4 Untreated pain from sternotomy, tube thoracostomy, and leg incision sites can induce delirium, 5 but opioids may also increase this risk. 6 Perioperative sedation and opioid-based analgesic regimens are potential risk factors for delirium that may be addressed with appropriate interventions. 7 Nonsteroidal anti-inflammatory drugs and acetaminophen (paracetamol) are commonly used as adjuvant analgesics. Since nonsteroidal anti-inflammatory drugs are avoided after cardiac surgery because of bleeding and kidney injury risk, acetaminophen may be particularly useful in this setting. Intravenous (IV) acetaminophen administration may be advantageous compared with oral or rectal routes because of variability in bioavailability. In some settings, IV acetaminophen has been shown to reduce inflammation and may confer central analgesic properties 8 and decrease opioid consumption in both opioid-naive and exposed patients. 9 Despite these properties, IV acetaminophen has not been studied in the context of delirium prevention. Dexmedetomidine, a selective α 2 receptor agonist, may have opioid-sparing effects 10 with anti-inflammatory properties 11 ; however, studies evaluating dexmedetomidine for prevention of delirium following cardiac surgery have shown mixed results.
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This study aimed to investigate the effect of IV acetaminophen vs placebo combined with IV dexmedetomidine or propofol on the incidence of postoperative delirium. It was hypothesized that postoperative IV acetaminophen for 48 hours as an adjuvant analgesic and dexmedetomidine as a sedative would reduce the incidence of in-hospital delirium following cardiac surgery.
Methods

Study Design
This randomized factorial trial was conducted at Beth Israel Deaconess Medical Center in Boston, Massachusetts, from September 2015 to April 2018. Institutional review board approval was obtained from the Committee on Clinical Investigations and all patients provided written informed consent. The study protocol has been previously published 15 and is available in eAppendix 1 in Supplement 1.
Study Participants
Patients aged 60 years or older undergoing coronary artery bypass graft surgery with or without aortic and/or mitral valve replacement requiring cardiopulmonary bypass were eligible for trial inclusion. Patients with a preoperative left ventricular ejection fraction of less than 30%, preexisting cognitive impairment, Alzheimer disease, Parkinson disease, medications for cognitive decline, history of recent seizures, serum creatinine levels above 2 mg/dL, liver dysfunction, recent history of alcohol misuse, English-language limitations, and hypersensitivity to study medications and patients undergoing emergent surgery were excluded. Participants who did not speak English were excluded because of their inability to complete the cognitive assessments, which have been extensively validated in English.
Randomization and Blinding
Patients were allocated using computer-generated block randomization of size 8 with the help of a research pharmacy to either acetaminophen or placebo as an adjunct analgesic and to either dexmedetomidine or propofol as a sedative. This resulted in 4 combinations (1:1:1:1) of analgesics and sedatives, namely, acetaminophen and dexmedetomidine, acetaminophen and propofol, dexmedetomidine and placebo, or propofol and placebo. To achieve blinding to analgesia group among patients, care teams, and research staff assessing outcomes, 1 g of IV acetaminophen and placebo (0.9% saline) were distributed in equal-volume IV bags. Given the distinct appearance of propofol, there was no blinding to sedation group.
Study Outcomes
The primary outcome was the incidence of postoperative inhospital delirium at any time during a patient's hospital stay. Delirium was measured daily until discharge with the Confusion Assessment Method (CAM) or CAM-ICU for intubated patients. The CAM is a standardized tool used for identification of delirium through a diagnostic algorithm based on 4 cardinal features of delirium, namely acute onset and fluctuating course, inattention, disorganized thinking, and altered level of consciousness. Secondary outcomes included duration of delirium, postoperative cognition at discharge, 48-hour breakthrough analgesic requirements, and ICU and hospital lengths of stay. Additional postoperative analgesic requirements were measured as the amount of opioid (IV morphine or hydromorphone) and oral analgesics required for pain control. This was calculated as the sum of (fentanyl dose × 2.4) + (hydromorphone dose × 4) + morphine dose + (oxycodone dose × 1.5).
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For context, a morphine equivalent dose of 90 morphine equivalents a day would correspond to 90 mg of hydrocodone or roughly 60 mg of oxycodone. Hospital length of stay was defined as the number of days admitted in the hospital following surgery and ICU length of stay was defined as the number of hours admitted in the ICU prior to transfer to the general floor. Postoperative cognitive decline was assessed as a secondary outcome using the 17 at baseline and discharge. Daily cognitive assessments were performed each day using a standard questionnaire comprising the Delirium Symptom Interview, a standard cognitive assessment consisting of tests of attention, orientation, and memory, and the CAM or CAM-ICU. Nonverbal (intubated) patients were administered the CAM-ICU, which includes both brief cognitive testing and the CAM algorithm to determine the presence or absence of delirium. Assessments were administered by study team members masked to treatment assignment and specifically trained in recognition and assessment of delirium and cognition. Post hoc analyses included delirium severity (CAM severity [CAM-S] score; range, 0 [best/no delirium] to 19 [worst]; MCID, 2 points), 18 median time to ICU discharge among patients with and without delirium, and postoperative pain. All reported pain scores (11-point scale from 0 [no pain] to 10 [worst pain]; MCID, 2 points) 19 were obtained from study participants by nursing staff blinded to the analgesic assignment and were entered into the medical record. The median and highest (worst) of these pain scores were recorded for analysis for each patient on each postoperative day.
The study protocol provides the schedules of enrollment, interventions, and assessments used in the trial. 15 Additional details of the study protocol are documented in eAppendix 1 in Supplement 1. Results of the postdischarge follow-up and biomarker analyses are not included in this article.
Adverse Event Assessments
Hypotension was predefined as a systolic blood pressure less than 90 mm Hg for 5 minutes or more. Bradycardia was defined as any heart rate less than 40/min. Adverse event data were collected from patients' medical records daily for a maximum of 10 days. In a post hoc analysis, the difference between groups in the lowest documented blood pressures was assessed.
Sample Size
A sample size of 58 patients was needed for each group, acetaminophen and placebo, to detect a 50% reduction in delirium incidence from a baseline delirium incidence of 50% using 2-sidedα=.05and80%power.Theexpected effect size in the primary outcome was based on a pilot study conducted at Beth Israel Deaconess Medical Center. 20 Previous studies have shown that reductions in the incidence of delirium exceeding at least one-third of the baseline rate are considered clinically meaningful; therefore, this study would be powered to detect a clinically meaningful difference. 21 A sample size of 120 patients who received the intervention was targeted to account for potential patient withdrawals. At the time of conception, this study was also interested in the effect of sedation type on the incidence of in-hospital delirium. Hence, the inclusion of this second factor was preplanned. It was therefore included in the factorial design to allow for generation of hypotheses with sedation techniques; however, the trial was powered only to detect differences between those who did and did not receive acetaminophen.
Statistical Analysis
Research Electronic Data Capture (REDCap) was used for data collection and included information on analgesics and sedatives, opioid dosage during the first 48 hours postoperatively, pain scores, patient delirium and cognition assessment data, adverse events, and demographic data. The primary analysis included all patients who were randomized and received at least 1 dose of the study medication. Patients who withdrew after receiving a study medication were still included in the analysis. Daily assessments of delirium were completed until the time of withdrawal. Data were abstracted from the medical record to assess secondary end points in patients who withdrew. Data are presented as means and standard deviations, medians and interquartile ranges (IQRs), or frequencies and proportions depending on variable type and distribution. Changes between groups are further presented as differences and 95% confidence intervals. The Shapiro-Wilk test was used to assess normality. Continuous data were assessed between groups using a parametric t test, Wilcoxon rank sum test, or Kruskal-Wallis test as appropriate. Differences in categorical variables, including the primary outcome (in-hospital delirium), were assessed with a χ 2 test (or a 2-tailed Fisher exact test when cell counts were small). Missing data were uncommon in the data set (<6%); therefore, no imputation was performed. Interrater reliability assessments of delirium, reported as percent agreement, κ, and weighted κ, were performed both for presence of delirium and for key features including acute change, inattention, disorganized thinking, and altered level of consciousness. The primary analysis focused on the relationship between the primary outcome, in-hospital delirium, and acetaminophen use. Given the factorial design of the study, an analysis was performed to determine whether an interaction was observed between groups. In this analysis, a regression model was created with in-hospital delirium as the outcome variable, including an interaction term between the sedative and analgesic groups. Prespecified secondary analyses were performed for outcomes in the factorial design, with 4 groups representing each of the acetaminophen and sedative combinations as well as for the relationship between sedative groups comparing patients who received dexmedetomidine with those who received propofol. No adjustment was performed for multiple testing; therefore, all results for secondary analyses should be interpreted as exploratory.
In post hoc analyses, Kaplan-Meier curves and a Cox proportional hazards model were used to compare time to experiencing delirium after confirming that the proportional hazards assumption was met. To test whether the proportional hazards were met, a time-varying covariate with group was included in the model (P = .56). Given the factorial design, this approach was replicated in models for all 4 factorial groups as well as for the pairwise comparisons (dexmedetomidine vs propofol and acetaminophen vs placebo) to ensure that this assumption was valid. No violations of this assumption were detected; therefore, no time-varying covariates were retained in the final model. Repeated-measures analyses including generalized estimating equations with robust variance were used to assess for differences in the median and worst daily pain scores between groups using mixed-model regression. SAS version 9.4 (SAS Institute Inc) was used for all analyses, with 2-sided P<.05 considered statistically significant. Full details of the statistical analysis plan are available in eAppendix 1 in Supplement 1.
Results
Study Population
A total of 140 patients provided informed consent and were enrolled, of whom 121 were randomized and a total of 120 received the study intervention and were subsequently analyzed ( Figure 1 
Study Drug Administration
Two patients in the dexmedetomidine group received propofol and 2 patients in the propofol group received dexmedetomidine in the first 6 hours. Five participants (2 in the placebo group and 3 in the acetaminophen group) missed 1 dose and 1 placebo participant received 1 additional dose of placebo. Four participants randomized to acetaminophen and 1 participant randomized to placebo received additional IV, oral, or rectal acetaminophen during the study period.
Despite these results, all analyses were performed using data from all randomized patients who received at least 1 of the 4 study medications.
In-Hospital Delirium
When conducting the analysis of the factorial groups, no significant interaction was observed between the sedation and analgesic groups (P = .62). Results of the main effects were therefore analyzed and are presented separately. Patients assigned to acetaminophen had a significantly lower incidence of in-hospital delirium, the primary outcome, compared with patients assigned to placebo (10% vs 28%; difference, −18%; 95% CI, −32% to −5%; P = .01) ( Table 2 ). In contrast, no significant difference was observed in the incidence of delirium (17% vs 21%; difference, −4%; 95% CI, −18% to 10%; hazard ratio, 0.8; 95% CI, 0.4-1.9; P = .54) between those who did and did not receive dexmedetomidine. Agreement was 100% and κ and weighted κ were 1.00 for all CAM variables collected.
Comparison of Acetaminophen vs Placebo
Patients who received acetaminophen experienced a shorter duration of delirium compared with placebo (median, 1 vs 2 days; difference, −1 day; 95% CI, −2 to 0 days; P = .03) ( Table 2 ). Postoperative cognition, as assessed via the median discharge MoCA score, was not significantly different between the 2 groups (median, 24.0 vs 24.0 points; difference, 0 points; 95% CI, −1.0 to 2.0 points; P = .29). Intensive .54
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did not receive acetaminophen for either worst (P = .44) or median (P = .21) pain scores ( Figure 2 ). In post hoc analyses, the worst delirium severity (CAM-S) score was not significantly different between those who did and did not receive acetaminophen (median, 9.0 vs 8.0 points; difference, 1.0 point; 95% CI, −2.0 to 3.0 points; P = .81); however, time to delirium onset was significantly different between those in the acetaminophen and placebo groups (hazard ratio, 2.8; 95% CI, 1.1-7.8) ( Figure 3) . Furthermore, in a post hoc analysis of ICU length of stay, the median time to ICU discharge was significantly higher in patients who experienced delirium as opposed to those who did not (median, 52. 
Comparison of Dexmedetomidine vs Propofol
When stratified by sedation group, duration of delirium, compared between those who did and did not receive dexmedetomidine, was not statistically significantly different (median, 1.0 vs 2.0 days; difference, −1 day; 95% CI, −2 to 0 days; P = .31) ( Table 2 ). The median MoCA score at discharge was not statistically different between those who did and did not receive dexmedetomidine (median, 24.0 vs 24.0 points; difference, 0.9 points; 95% CI, −1.0 to 1.0 points; P = .55). Median lengths of stay in both the ICU (median, 32.0 vs 29.7 hours; difference, 2.3 hours; 95% CI, −3.2 to 5.0 hours; P = .66) and the hospital (median, 8.0 vs 8.0 days; difference, 0 days; 95% CI, −1 to1day;P = .71) were not significantly different between the dexmedetomidine and propofol groups. Patients who received propofol had larger total morphine equivalent doses given in the first 48 hours postoperatively compared with patients who received dexmedetomidine (median, 328.8 vs 397.5 μg; difference, −69 μg; 95% CI, −155 to −4 μg; P = .04). In post hoc analyses, worst and median pain scores were not statistically different between sedative groups (P = .39 and P = .13, respectively) ( Figure 2 ). In post hoc analyses, the severity of delirium (median CAM-S score, 6.5 vs 9.0 points; difference, −2.5 points; 95% CI, −3.0 to 2.0 points; P = .39) was not statistically different between groups.
Comparison of All 4 Randomization Groups
In a prespecified exploratory analysis of differences across all 4 groups, there was no statistically significant difference in the incidence of in-hospital delirium (P =.07)( Table 3) . Specifically, in a logistic regression model including all 4 groups with placebo-propofol as the reference category, the acetaminophen-propofol group and the placebo-dexmedetomidine group showed no statistically significant difference in the odds of developing in-hospital delirium (odds ratios, 0.35 [95% CI, 0.09-1.28] and 0.85 [95% CI, 0.28-2.61], respectively). However, a statistically significant difference was observed in the acetaminophen-dexmedetomidine group (odds ratio, 0.17; 95% CI, 0.03-0.87). These and other results for secondary end points showed effect sizes consistent with those observed in the primary analysis.
Adverse Events
Clinical outcomes and adverse events were not significantly different when stratified by randomization group (eTable 2 in Supplement 2). Fourteen patients each in the placebodexmedetomidine and acetaminophen-propofol groups (46% and 45%, respectively) and 7 patients each in the acetaminophen-dexmedetomidine and placebo-propofol groups (24% and 23%, respectively) experienced at least 1 episode of hypotension postoperatively. One patient (3%) in the placebodexmedetomidine group and 1 patient (3%) in the acetaminophen-propofol group experienced postoperative bradycardia.
In a post hoc analysis, although roughly one-third of patients met the prespecified threshold for hypotension (systolic blood pressure <90 mm Hg for >5 minutes), the median of their lowest documented systolic blood pressure measurements was 83 (IQR, 79-86) mm Hg, which did not differ by group (P =. 7 4).
Discussion
In this randomized trial, patients who received scheduled IV acetaminophen analgesia in the first 48 hours postoperatively demonstrated a decreased in-hospital incidence of delirium compared with placebo. Additionally, delirium duration, ICU length of stay, and opioid and/or opioid equivalent use in the immediate postoperative period were lower in participants randomized to receive acetaminophen. In sedation analyses, although opioid use was significantly lower in the dexmedetomidine groups compared with the propofol groups, there was no statistically significant difference in delirium or length of stay. To our knowledge, this study is the first to show Change from baseline, median ( .93
Time-related outcomes Reduced opioid consumption 6 may partially explain the mechanism behind the reduction in the incidence of delirium seen in the present study. The finding of a decreased ICU length of stay in patients receiving IV acetaminophen was similar to the results from a meta-analysis in which critically ill patients with delirium had a 1-day longer mean length of ICU stay than those without delirium. 27 Furthermore, increased inspiratory lung capacity 24 and better pain relief with patient satisfaction 23 favor a shorter ICU stay, both of which could potentially be achieved more effectively with a successful opioid-sparing technique. These positive benefits need further exploration in larger clinical trials, both in the setting of enhanced recovery after cardiac surgery as well as in the face of the current opioid epidemic. Although dexmedetomidine reduced opioid use in bariatric surgical patients, 10,28,29 its role in reducing postoperative delirium following cardiac surgery has yielded contradictory results. 12, 13, 30, 31 In this study, although a decrease in opioid consumption in the first 48 hours postoperatively was observed, no statistically significant trend was observed in delirium incidence, severity, or duration. In addition, no interaction was found between dexmedetomidine and acetaminophen in reducing delirium incidence. Further studies in a larger cohort are needed to truly elucidate the effect of dexmedetomidine on aspects of delirium and cognition.
Limitations
This study has several limitations. First, although powered to detect a difference in postoperative delirium between those who did and did not receive acetaminophen, the sample size was relatively small and the incidence of delirium was lower in this study compared with the pilot study used to perform the power calculation. It is therefore possible that the large effect size observed may not be replicated in larger trials. It is also possible that group interactions could be limited by the sample size, specifically the interaction between IV acetaminophen and dexmedetomidine. Given the small sample size, inferences should be interpreted with caution. Second, anesthetic management was left to the discretion of treating anesthesiologists. This may have affected the outcome given the potential differing effects of anesthetic drugs on the development of postoperative delirium. However, practice variability in perioperative care was minimized with a protocolized cardiac surgical environment and preservation of randomization would be expected to minimize confounding from any anesthetic practice differences. Third, it was not possible to blind the sedative (propofol or dexmedetomidine) to the study team. However, the primary outcome was based on blinded, placebo-controlled exposure to IV acetaminophen. Fourth, it is possible that during daily delirium assessments, some periods of acute-onset inattention, disorganized thinking, or altered level of consciousness may have been missed, potentially leading to misclassification of these outcomes. Despite this, routine testing once per day is an accepted method of diagnosing delirium. 32 Fifth, the postoperative analgesic regimen was nursing driven (standard of care) even though patient-controlled analgesia would have been ideal, although randomization and the triple-blind design would have mitigated this. Sixth, the limited sample size from a single center and restrictive inclusion may place some limitations on generalizability. Specifically, nonEnglish-speaking participants were excluded because of their inability to complete the cognitive assessments. The resulting cohort was predominantly white and male. It is possible that the findings observed may not be generalizable to other institutions or to people of other racial and ethnic backgrounds. As this was a single-center study, the results should be replicated in a larger multicenter trial.
Conclusions
Among older patients undergoing cardiac surgery, postoperative scheduled IV acetaminophen, combined with IV propofol or dexmedetomidine, significantly reduced the incidence of in-hospital delirium compared with placebo. Additional research, including comparison of IV vs oral acetaminophen and other potentially opioid-sparing analgesics on the incidence of postoperative delirium, is warranted.
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STUDY PROTOCOL
Purpose
The goal of this randomized clinical trial is to evaluate the effect of intravenous (IV) acetaminophen vs placebo, combined with IV propofol vs dexmedetomidine, for postoperative sedation and analgesia respectively, in adult patients 60 years or older undergoing coronary artery bypass grafting (CABG) or combined CABG/valve surgeries to assess the incidence of postoperative delirium with the Confusion Assessment Method (CAM or CAM-ICU). It is possible that there may be a benefit to those enrolled in the dexmedetomidine and acetaminophen group, as their incidence of delirium could possibly be reduced, however we cannot guarantee this.
Additionally, this study will assess postoperative cognition following cardiac surgery through 1-year using a cognitive assessment scale and compare postoperative analgesic requirements in patients with and without IV acetaminophen.
Effect Patients were randomized to one of four factorial groups which included randomization to receive postoperative analgesia with intravenous acetaminophen or placebo every 6 hours for 48 hours. In addition, patients were randomized to receive postoperative sedation starting at chest closure and continued for up to 6 hours postoperatively or until extubation with intravenous dexmedetomidine or propofol.
The incidence of postoperative in-hospital delirium was assessed daily using the CAM or CAM-ICU during the patient's hospitalization. In addition, follow up assessments were conducted at one month and one year.
Study Discontinuation
Patient request or any serious adverse event thought to be related to study procedures 
Key Roles
Significance and Background
Approximately 50% of patients have postoperative delirium following cardiac surgery 1 . The growing body of evidence suggests that in-hospital delirium is associated with poor hospital outcomes, including a tenfold increased risk of death, and a fivefold increased risk of nosocomial related complications 2 . Delirium has also been associated with serious longer term outcomes such as poor functional recovery, and most recently, impaired cognitive function for up to one year after cardiac surgery 3 . Importantly, intervenable factors, such as perioperative sedation and analgesia with opioids may contribute to the etiology of delirium.
In the setting of cardiac surgery done increasingly in older patients, there is an urgent need to test alternative sedation and complementary analgesic techniques.
Dexmedetomidine, a selective alpha-2 receptor agonist, provides sedation without causing respiratory depression. Dexmedetomidine is also suggested to have an opioid sparing effect that makes it a unique sedative drug. Currently used sedation drugs (midazolam) release deliriogenic mediators through binding of Gamma-aminobutyric Acid (GABA) receptors. Dexmedetomidine has no effect on the GABA receptors. Although these characteristics suggest dexmedetomidine to be a unique and promising drug for sedation following cardiac surgery, its efficacy on reducing the incidence, duration and long term effects of delirium has not been studied thoroughly.
Studies involving use of dexmedetomidine in an attempt to reduce the incidence of delirium in cardiac surgical patients provide conflicting results. One meta-analysis concluded that dexmedetomidine in cardiac surgery shortened the ventilator time (but not the Intensive Care Unit (ICU) or hospital length of stay), reduced the incidence of postoperative ventricular arrhythmias and delirium in cardiac surgical patients 4 . However, there are several issues with this meta-analysis, particularly for the systematic assessment of postoperative delirium. The problems with the four studies that formed the basis of this meta-analysis are explained in the next few paragraphs.
In a retrospective study 5 of administrative database from 250 hospitals, the incidence of postoperative delirium following cardiac surgery was significantly decreased with associated cost savings in the dexmedetomidine group. This study compared two regimens (dexmedetomidine, propofol plus narcotics vs. propofol vs. narcotics). Propofol was used in the dexmedetomidine group as well. This trial specifically does not mention how delirium was assessed in individual hospitals.
A randomized controlled trial 6 comparing dexmedetomidine/propofol to morphine/propofol in cardiac surgery patients showed a decreased duration of delirium (5 days to 2 days) in the dexmedetomidine group. This study found a similar incidence of delirium in both the groups. Propofol was used as a sedative in both the groups and this could have attributed to similar incidences of delirium in both the groups. There is a possibility the study was not powered adequately as the baseline incidence of delirium in the control group was a surprisingly low 15%, much lower than other cardiac surgery studies that have employed state-ofthe art delirium measures. This study used CAM-ICU for assessing delirium both in intubated and extubated patients. While the CAM-ICU, a delirium assessment that does not require any verbal responses by the patient, is state-of-the-art for intubated patients, it has reduced sensitivity for delirium in verbal patients. This design could have underestimated the incidence of delirium.
The third study 7 included in the meta-analysis was a prospective, randomized, open labeled trial comparing three groups (dexmedetomidine, midazolam, and propofol). This study reported a dramatically decreased incidence of delirium in the dexmedetomidine group, 3%, compared to 50% in propofol and midazolam groups. This was a small study, with only 118 patients were recruited and only 90 patients finally analyzed, with 28 patients randomized patients excluded for protocol violations. This introduces a significant selection bias. Furthermore, a 94% reduction in the incidence of delirium was seen in this study. This effect size is almost implausibly large and has not been seen in other studies. Nevertheless, this study can provide a framework for sample size for future studies assuming the best case scenario.
The final study 8 included in the meta-analysis was a prospective randomized control trial of 89 patients undergoing non emergent CABG. In this study, a patient satisfaction questionnaire was used to assess pain, comfort and extubation process between intravenous dexmedetomidine and propofol groups. One patient in each group was reported to have delirium. This study was not designed to identify patients with delirium with any specific tools such as CAM and thus could have grossly underestimated delirium incidence. Thus, the meta-analysis represents a combination of poorly designed studies with differing measurements, and is extremely unlikely to create a significant impact or practice change among clinicians. Therefore, these findings will not result in a practice change in cardiac surgical intensive care units.
Postoperative pain following cardiac surgery can be due to the sternal incision, chest tube sites and leg incisions. Current pain relief strategy includes postoperative opioid administration (IV morphine or hydromorphone). While, inadequate pain relief increases the risk of postoperative delirium, opioids with their psychoactive properties also increase the risk of postoperative delirium, especially in elderly patients. A multimodal balanced postoperative pain management is advantageous and provides several beneficial effects. The options in cardiac surgery would include nonsteroidal anti-inflammatory drugs and acetaminophen. Their postoperative use decreases the exposure of older patients to opioids and can be an effective delirium prevention strategy. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) have contraindications after many kinds of surgery, including cardiac surgery, which include their deleterious effects on the gastrointestinal tract and renal function.
Acetaminophen has no psychoactive properties and is an attractive option as it lacks bleeding risks associated with nonsteroidal agents. Acetaminophen is for the most part safe but could cause liver dysfunction in rare instances. Oral administration of acetaminophen achieves limited blood levels in critically ill patients and therefore has limited efficacy. IV acetaminophen addresses this by allowing administration in critically ill patients and providing superior bioavailability to oral preparations 9 . This approach has been shown to reduce pain intensity and also decrease the rescue intravenous morphine used during the postoperative period.
IV acetaminophen has never been studied in the context of cardiac surgery and delirium prevention. Additionally, comparing IV acetaminophen as an adjuvant analgesic in combination with IV propofol or IV dexmedetomidine may ascertain additive or synergistic effects on delirium prevention. Our randomized, single-blind, pre-pilot study with 12 patients showed that in patients who received IV acetaminophen as adjuvant analgesic (N=6), the incidence of delirium was 17% (1/6) compared to 67% (4/6) in those who did not. The total incidence was 42% (5/12). Despite the small sample size, this provocative finding suggests that IV acetaminophen with propofol or dexmedetomidine may offer a significant benefit in reducing the incidence of delirium following cardiac surgery. If this benefit is proved in a larger study as proposed, this will have a significant impact in patient care and satisfaction.
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Subject Recruitment
Screening Eligible participants will be identified at preadmission testing clinic appointments, in the cardiac catheterization lab or on the medical floors. At this time all inclusion and exclusion criteria will be assessed.
Inclusion Criteria
Adult patients ≥ 60 years of age who are undergoing CABG with/without valve (aortic and/or mitral) procedure requiring bypass.
Exclusion Criteria Patients will be excluded if they had a preoperative LVEF <30% emergent procedure, isolated aortic surgery, pre-existing cognitive impairment, Parkinson's disease, Alzheimer's disease, prophylactic medications for cognitive decline, active history of drug or alcohol abuse, serum creatinine >2mg/dL , liver dysfunction, non-English speaking, seizures in the last three months, emergent procedure or hypersensitivity to study drugs or procedures.
Adult patients unqualified or incapable of giving legal consent will be excluded.
Informed Consent
Written informed consent will be obtained prior to initiation of any study-specific procedures. Consent will be obtained by one of the participating researchers of the study. At the time of consent, all study procedures will be explained in detail, including the associated risks and benefits. The subjects will have the opportunity to ask any and all questions, and will be reminded that participation is voluntarily. All subjects will be consented with curtains drawn or the door closed, assuring patient privacy. Written informed consent will then be obtained from interested participants. The original signed form will remain with the investigator in the study file. Copies will be given to the patient and filed in the official medical record as well.
Randomization and Blinding
After obtaining written informed consent, participants will be randomized to one of four groups by the research pharmacy using a sequence of computer -generated random numbers. Blocked randomization will be used to assign recruited participants to one of four combinations of analgesics and sedatives in a 1:1:1:1 allocation: (1) acetaminophen and dexmedetomidine, (2) acetaminophen and propofol, (3) placebo and dexmedetomidine, or (4) placebo and propofol. In order to blind the patient, the care team, and the research staff assessing outcomes to the analgesia group, 1 gram of IV acetaminophen and placebo (0.9% saline) were distributed in equal volume IV bags. Due to the distinct appearance of propofol, there was no blinding to the sedation group.
Study Procedures Overview
The proposed study is a randomized, placebo controlled, factorial design, triple blind, clinical trial designed to evaluate the effect of postoperative IV acetaminophen versus placebo, combined with IV propofol versus dexmedetomidine, on postoperative delirium among older patients undergoing cardiac surgery. Patients will be randomized to one of four groups (1) acetaminophen and dexmedetomidine, (2) acetaminophen and propofol, (3) placebo and dexmedetomidine, or (4) placebo and propofol. It is possible that the participants who receive acetaminophen and dexmedetomidine may benefit from the study as their incidence of delirium could possibly be reduced, however we cannot guarantee this.
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Study Groups
The four treatment arms will be:
1. Acetaminophen and dexmedetomidine 2. Acetaminophen and propofol 3. Placebo and dexmedetomidine 4. Placebo and propofol
All study medications will be administered intravenously and doses will be weight-based. Acetaminophen/placebo will be administered on ICU transfer and thereafter every six hours for a total of eight doses. Volume of the placebo (saline) will match that of IV acetaminophen at 100ml 0.9% sodium chloride. Acetaminophen administration in any form other than the blinded study medication during this time was not allowed. Propofol or dexmedetomidine was started during chest closure and continued for up to six hours postoperatively or until extubation, whichever occurred first. Participants in the dexmedetomidine groups will get a bolus dose of 0.5 -1mcg/kg IV during chest closure, followed by a maintenance infusion of 0.1 -1.4 mcg/kg/hour. Propofol infusions will be avoided in these participants. Patients in the propofol groups will receive propofol at a dose of 20 -100 mcg/kg/min and dexmedetomidine infusions will be avoided in these patients.
Pharmacy
Once a participant is enrolled, the study team will contact the research pharmacy to randomize the subject.
The research pharmacy at Beth Israel Deaconess Medical Center will be responsible for preparation and distribution of study medications. Study team members will physically deliver the first dose of the acetaminophen/placebo (saline) medication. Subsequently the research pharmacy will be responsible for delivering the study medication to the ICU. Any unused drug will be returned to the research pharmacy for disposal.
Study Assessments
The assessments will be completed at specific time points. Once consent is obtained, a trained study team member blinded to treatment allocation will proceed with a baseline cognitive and delirium assessment. This will include the assessment of cognitive function using the Montreal Cognitive Assessment (MoCA), supplemented with days of the week backwards (DOWB) and months of the year backwards (MOYB) for additional attention testing, the Delirium Symptom Interview (DSI) to capture symptoms of delirium and the Geriatric Depression Scale (GDS) to assess for baseline depression. Using data from the cognitive testing and DSI, a study team member will complete the Confusion Assessment Method (CAM), which includes a diagnosis of delirium using the CAM diagnostic algorithm. This detailed assessment will take no more than 20-30 minutes. Every day, a study team member will administer a standard cognitive assessment and the CAM. These daily assessments will take approximately 10-15 minutes. On the day of discharge, the MoCA with DOW and MOY, the DSI, and CAM will be completed. (If the discharge assessment was performed in anticipation of discharge on a specific day but the discharge was delayed (i.e. logistical reasons, clinical reasons), this will not be considered a protocol deviation.) A follow-up assessment will be administered at 1 month and 1 year post-discharge over the telephone and will include a telephone version of the MoCA known as the T-MoCA, DSI, GDS, and CAM. Assessments will be administered and scored by trained study team members.
If daily assessments are negative for three consecutive days (i.e. days 5, 6 & 7), they will then be completed every other day until date of discharge. In addition, these assessments will be done at the patient's convenience to ensure ability to finish the evaluations. The table below outlines the assessments at various time points. The delirium research assessments will not be provided to the treating clinicians. Treating clinicians will assess and treat delirium as usual, including assessment and correction of reversible causes, behavioral management and use of IV haloperidol for agitation, if needed. Rescue doses of haloperidol will be recorded in the study.
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Blood Acquisition Blood will be collected at four times points 1) Baseline: at the time of the pre-operative study assessments or on day of surgery; 2) on POD 1 while in the intensive care unit; 3) on POD 2 while in the intensive care unit; and 4) within 48 hours prior to discharge or days 8-10, at the latest. A total of 80 ccs of blood will be collected. Blood samples will be collected into sterile vacuum tubes using either a vacutainer or butterfly system, at the preference of the phlebotomist. All samples will be centrifuged. The plasma and buffy coat will be separated from red blood cells, aliquoted into small samples, labelled and frozen at -80 Celsius for future use. Blood samples will be stored in a biomarker bank for further analysis.
Blood Storage Using all blood samples from our participants, we will create a bio-repository of genetic material and plasma, a resource for future biomarker discovery studies. The banked specimens will be coded and stored in a -80 Celsius freezer at a BIDMC facility. A list linking study numbers to participants will be kept in a secure computer database. In the future, the frozen plasma or DNA may be shared with other scientists studying a similar relationship between delirium and genetic factors after a formal application procedure and scientific review process approved by the IRB. Information including contact information, rationale for studying data and intended use of data may need to be approved by CCI/IRB prior to sharing data. All such studies will be carried out under controlled access and under the close supervision of the study team. In these cases, the study investigators will maintain confidentiality of the specimens by maintaining the de-identification of
patient information to the other scientists. We plan to store these specimens indefinitely. None of the results from these studies will be shared with participants or their family members and none of the genetic information obtained will be included in the patient's medical records. All patients approached for participation in study will also need to agree to participation in blood collection/storage as noted in informed consent.
Follow Up A follow-up assessment will be administered at 1 month and 1 year post-discharge over the telephone and will include a telephone version of the MoCA known as the T-MoCA, DSI, GDS, and CAM.
Study Outcomes
Primary Outcome
The primary objective of this study was the incidence of in-hospital delirium at any time during a patients' hospital stay.
Secondary Outcomes
The secondary outcomes included duration of delirium, postoperative neurocognition at discharge, 48-hour breakthrough analgesic requirements, and ICU and hospital lengths of stay.
Data Collection
The participant's demographic data such as age, sex, ethnicity, race and body mass index will be recorded. Patient comorbid conditions, surgery and anesthetic drugs used will be obtained from Society of Thoracic Surgery database and Anesthesia Information Management System, which is a clinical outcomes registry that records and assesses the care of adult patients undergoing cardiac procedures at participating hospitals. Pertinent characteristics include: preoperative medications, comorbidities, surgical characteristics, and postoperative outcomes, including 30 day mortality and major adverse events like renal failure during hospital admission. Information on the sedatives and analgesics given within six hours prior to initiation of the cognitive assessment will be recorded, as to determine whether there is an effect on performance. The total opioid dosage administered during the first 48 hours post operatively, pain scores and patient delirium assessment data will be collected using REDCap. REDCap is a web-based application that allows customized data collection and entry. The study team will build and maintain the case report form electronically. Additionally, internal audits will be conducted to ensure data completion and data quality. Data will be kept secure in computers with password protection. All data will be analyzed with modified intention to treat basis, in which all subjects who receive at least one dose of a study medication will be included.
Data Security and Storage
All data will be kept secure in the password-protected BIDMC network servers. The paper format will be stored in locked file cabinets during the study period. Study data will be entered in datasheets and stored on a secure password-protected computer on the BIDMC network. Each patient will be assigned a studyspecific ID number. The data will have all HIPAA identifiers removed and a random study number assigned to each patient.
Safety Reporting
Our patient population is by definition undergoing high risk surgery and is critically ill. It is expected that they will have a number of unrelated adverse health events during the course of their hospital stay. The potential adverse effects such as the number of episodes of hypotension (predefined as < 90mm systolic for 5 minutes or more), and bradycardia (predefined as <40 beats per minute), will be collected from the ICU charts.
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Therefore, we will limit the scope of our AE monitoring and reporting to the following: o All Serious Adverse Events, including an unexpected death, believed to be related to the study o Unexpected, non-serious Adverse Events believed to be possibly or probably related to the intervention Evidence for adverse events will be assessed daily during the hospital stay, for a maximum of 10 days.
Statistical Analysis
Please refer to the Statistical Analysis Plan (SAP) for details of the power calculation and analyses.
Benefits to the Subject
There is a possible benefit to those enrolled in the dexmedetomidine and acetaminophen group, as their incidence of delirium can possibly be reduced, however we cannot guarantee this. Society as a whole will benefit in the future as a result of knowledge gained from the research.
Risks to the Subject
Risk of the Drugs Used
The drugs dexmedetomidine and acetaminophen are FDA approved for sedation and analgesic purposes. Bradycardia and hypotension are less common side effects with dexmedetomidine and in an intensively monitored setting of cardiac surgical ICU, the risks of bradycardia and hypotension can be managed effectively. Liver dysfunction is a rare side effect associated with IV acetaminophen. However, the drug is commonly used already in the perioperative setting routinely as the benefits seem to outweigh the risks. No routine monitoring is done for liver dysfunction in the current standard of care.
Risk Associated with Blood Draw
There is a small risk of phlebotomy to obtain serum for the serum biomarker assays at four time points during the study. Wherever possible, the serum collection will be obtained at the same time as phlebotomy and other labs for routine clinical laboratory work, thereby eliminating an additional risk imposed by a separate phlebotomy for study purposes. However, in rare cases such as at the time of discharge, patients may require a separate lab draw. The risks of the phlebotomy procedure itself are minimal and are primarily related to pain or bruising at the needle puncture site. Since the amount of blood required at each time point is small the risks from anemia or blood loss are negligible. The blood draws will total only 80 cc's over a maximum of four weeks, which is considered minimal risk.
Risk of Breach of Confidentiality
Patients will be referred to by a study number, and records will be password protected on BIDMC network servers. No identifiable data will be shared with the funding agency, or across institutions. The information that we collect from this research project will be kept confidential. All information will be stored in a HIPAA compliant database.
Risk/Benefit Ratio The drugs used for this study are approved by the FDA for sedation and analgesic purposes. When monitored in the intensive care setting, the risks of lower blood pressures or heart rates are far too small compared to the benefits of decreased delirium following cardiac surgery.
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Inducements
No inducements will be offered. Neither patients nor healthcare providers will be paid as part of their participation in the study.
Participant Withdrawals
Throughout the study participants will be reminded that participation is entirely voluntary and that they have the option to withdraw at any time, for any reason.
Subject Protection
Patients will be contacted directly for this study. The informed consent will be explained and obtained in a secure and private location such as the preadmission testing clinic, cardiac catheterization holding areas, cardiac surgery clinic, and/or in the pre-operative holding area. Patients will be informed that their decision to participate or not to participate will in no way affect their relationship with their health care provider. Furthermore they will still receive all information about their analgesic management, as is the standard of care. Patients will also have the ability to discontinue their participation at any time.
Introduction
This Statistical Analysis Plan describes the analysis of the prospective randomized controlled trial that has been reviewed and approved by the Committee on Clinical Investigations at Beth Israel Deaconess Medical Center (2014P000413) and will be conducted in accordance with all applicable human subjects' research requirements and applicable federal regulations.
Study Aims
Briefly, this randomized, factorial clinical trial evaluates the effect of intravenous acetaminophen versus placebo, combined with intravenous propofol versus dexmedetomidine, for postoperative sedation and analgesia respectively, in adult patients 60 years or older undergoing coronary artery bypass grafting (CABG) or combined CABG/valve surgeries to assess the incidence and duration of postoperative delirium.
Study Design
This is a single-center randomized controlled factorial trial of two sedative and two analgesic regimens.
Study Population and Sites
The study will prospectively enroll patients undergoing cardiac surgery at Beth Israel Deaconess Medical Center in Boston, Massachusetts. This includes patients enrolled between September 2015 and April 2018.
Randomization
Randomization will be by pre-prepared using a computer generated block randomization in SAS 9.3. Details of the block size are kept confidential until the completion of study enrollment. This schema will be created by the unblinded statistician (Ariel Mueller, MA) and sent to the research pharmacy. Members of the research pharmacy will be responsible for preparing and dispensing the study medications following an active order for study medications. Specifically this includes preparation and blinding of the placebo in accordance with the study randomization schema.
Patients will be randomized to one of four groups in a 1:1:1:1 fashion. This includes:
• Acetaminophen and Dexmedetomidine • Acetaminophen and Propofol • Placebo and Dexmedetomidine • Placebo and Propofol
Primary Endpoints
The primary endpoint will be the incidence of in-hospital delirium. This is assessed via the Confusion Assessment Method (or CAM-ICU for intubated patients) daily postoperatively, as specified in the study protocol. If a patient is noted to be positive for delirium on any postoperative day, they will have been documented as achieving the primary study endpoint.
Our pre-specified primary analysis will assess the incidence of delirium between patients receiving IV acetaminophen versus placebo.
Secondary Endpoints
Secondary outcomes for this study include:
• Duration of delirium o Definition: This will be calculated as the day of hospital discharge minus the day of surgery plus one. This will be assessed as a continuous variable and reported in days.
• Predefined potential adverse effects of the study drugs including:
o Number and duration of episodes of hypotension ▪ Definition: This is predefined as less than 90 mm Hg systolic blood pressure for five minutes or more o Number and duration of episodes of bradycardia ▪ Definition: This is predefined as less than 40 beats per minute.
• The proportion of patients who complete the protocol successfully will be measured.
• If this sedation and analgesic regimen is abandoned by the clinicians, the reason will be qualitatively described at the end of the study.
• Levels of inflammatory biomarkers
Covariates Trial data will be collected managed using REDCap electronic data capture tools hosted at Beth Israel Deaconess Medical Center. REDCap (Research Electronic Data Capture) is a secure, web-based application designed to support data capture for research studies, providing 1) an intuitive interface for validated data entry; 2) audit trails for tracking data manipulation and export procedures; 3) automated export procedures for seamless data downloads to common statistical packages; and 4) procedures for importing data from external sources. The REDCap system includes validation rules for data entry to help ensure data accuracy, and has a full audit trail of data entry and changes.
Data collection includes the participant's demographic data such as age, sex, ethnicity, race and body mass index will be recorded. Patient comorbid conditions, surgery and anesthetic drugs used will be obtained from Society of Thoracic Surgery database and Anesthesia Information Management System, which is a clinical outcomes registry that records and assesses the care of adult patients undergoing cardiac procedures at participating hospitals. Pertinent characteristics include preoperative medications, comorbidities, surgical characteristics, and postoperative outcomes, including 30 day mortality and major adverse events like renal failure during hospital admission. Information on the sedatives and analgesics given within six hours prior to initiation of the cognitive assessment will be recorded, as to determine whether there is an effect on performance. The total opioid dosage administered during the first 48 hours post operatively, pain scores and patient delirium assessment data will be collected using REDCap.
The overall flow and reporting of study recruitment, enrollment and follow up will follow the CONSORT recommendations for the reporting of randomized controlled trials.
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Sample Size Estimation
This is a prospective, randomized, placebo controlled, double-blinded, factorial design study consisting of 120 patients to assess the incidence and duration of postoperative delirium following cardiac surgery. From the previous delirium studies conducted at our institution, the baseline delirium incidence was 50%. The pilot study showed a 66% reduction in the incidence of delirium. For the power calculation, a 50% reduction in the delirium incidence was used. Each group needed 56 patients (alpha=0.05 and 1-Beta=0.80). This study will not be powered for secondary outcomes.
Because complete data from 112 patients is required in order for analysis, we plan to enroll enough patients to obtain data from 120 patients who received the study intervention (60 patients per group -acetaminophen vs. no acetaminophen). We estimate that approximately 150 patients will be enrolled (consented) in order to achieve this sample size. This increase is required because it is possible that patients can be withdrawn both before randomization (i.e. cancelled surgery) as well as after randomization but before receiving the study intervention (i.e. change in surgery type intraoperatively). Enrollment will be stopped once a total of 120 randomized patients have undergone surgery and received the study medications.
General Approach to Statistical Analyses
Baseline and demographic characteristics will be summarized and presented using descriptive statistics. Continuous data will be presented as means ± standard deviations or medians (interquartile range) depending on the distribution of the data. The Shapiro-Wilk test will be utilized in order to determine whether or not the data follows a Gaussian distribution. Differences in continuous data between study groups will be assessed using a parametric t-tests or Wilcoxon Rank-Sum tests as appropriate. Categorical data will be presented as frequencies and proportions and assessed with a chi-square test. In the event that cell counts are small (less than 5), we will employ the use of a Fisher's Exact test. For all analyses two-sided p-values less than 0.05 will be considered statistically significant. SAS 9.3 (SAS Institute Inc., Cary, NC) or later will be utilized for all analyses.
Analyses will be performed on a modified intention to treat basis, in which all patient who receive at least one dose of any of the four study medications will be included.
Analysis of the Primary and Secondary Outcomes
The DEXACET trial has been designed as a factorial, randomized controlled trial with four treatment groups. We will therefore aim to test 1) the effect of acetaminophen versus placebo and 2) the effect of dexmedetomidine in comparison to propofol in the event that there is no interaction between treatment effects. However, the first of these (the effect of acetaminophen) is considered the most interesting and the study has been powered to answer this question using an unadjusted chi-squared test.
To test whether or not there is an interaction we will compose a logistic regression model include indicator variables for the acetaminophen group as well as the dexmedetomidine group. We will further include an interaction term in this model composed of the indicator variables multiplied together. If there is a significant interaction between groups when assessing the incidence of in-hospital delirium, we will interpret the results stratified by all four groups, presenting the main effects only after taking into account the other factor, in a 'inside the table analysis'. If the interaction term is not significant we will present the main effects by pooling data across the other factor.
Kaplan Meier curves and a Cox proportional hazards model was used to compare time to experiencing delirium, after confirming the proportional hazards assumption is met. To test whether the Proportional
Hazards (PH) assumption holds, we will include a time varying covariate with group in the model. Given the factorial design this approach will be replicated in models for all four factorial groups, as well as the pairwise comparisons (dexmedetomidine vs propofol; acetaminophen vs placebo) to ensure this assumption remains valid. In the event that this assumption is not valid, we will include a time-varying covariate in the model. Hazards ratios and their associated 95% confidence intervals will be reported.
Repeated measures analyses including generalized estimating equations with robust variance will be employed to assess for differences in continuous variables that are measured at multiple time points over time between groups using mixed model regression.
Interrater reliability assessments of delirium will be assessed for approximately 10% of patients. This includes assessment of both for the presence of delirium, and for key features including acute change, inattention, disorganized thinking and an altered level of consciousness. Percent agreement, kappa and weighted kappa will be reported.
Given the nature of a randomized controlled trial, we do not anticipate seeing differences between groups in baseline characteristics; however, we will perform a secondary analysis, adjusting for any differences observed between groups and presenting adjusted odds ratios and their associated 95% confidence intervals.
Interim Analyses
There will be no interim analysis.
Missing Data
The frequency and percentage of missing values for each variable will be collected, analyzed and reported as necessary. If there are missing values for the outcome variable(s), individual patients will be excluded. Highly incomplete covariates (>33% of observations missing) will be excluded from analyses. In the event that a variable is missing more than 10% of the time we will consider imputation. If missing values are missing at random (MAR) or not at random (MNAR), multiple imputation will be performed. Missing values, selection or exclusion of observations and variables and handling of missing values in the statistical analysis will be describes carefully and sensitivity analysis will be provided in the manuscript.
Statistical Analytical Issues
Adjustments for Covariates Given the randomized nature of this study, there will be no covariate adjustment in the primary analysis. If differences between groups persist after randomization we will perform a post hoc analysis including variables that are significantly differ between groups.
Multiple Comparisons There will be no adjustment for multiple testing. Results of secondary outcomes and post hoc analyses will therefore be considered exploratory.
Examination of Subgroups
Our pre-specified primary analysis will assess the incidence of delirium between patients receiving intravenous acetaminophen versus placebo. Predefined subgroup analyses will be performed for our primary and secondary outcomes for the following groups:
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• All four factorial groups including both sedatives (dexmedetomidine and propofol) and analgesics (acetaminophen and placebo).
Post-hoc Analyses
Post-hoc data driven analyses are allowed after the following are undertaken: 
VIII.
If not within fast track criteria then page the ICU provider immediately to discuss plan of action and if not ready for extubation return to step IV.
IX. Meets Extubation Criteria
• Decision to proceed with extubation may be made by the CVICU RN, in coordination with the CVICU RT • For patients with a difficult airway, the plan to extubate should be discussed with the intensivist and ICU provider, prior to extubation X. Extubate • Head of Bed (HOB) should be elevated at least 60° unless contraindicated • Endotracheal Tube (ETT) should be suctioned prior to extubation, with hyperoxygenation of the patient before and after suctioning (use the Suction 100% function on ventilator).
• Suction mouth with Yankauer immediately prior to extubation.
• Nasogastric tube, if present, should be aspirated and discontinued.
• Explain procedure to patient, informing them that a strong cough will be necessary as the ETT is withdrawn; explain that patient may be unable to speak for a time.
• Patient to be placed on face tent/nasal cannula to provide adequate SpO2 ≥ 92%
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POST-EXTUBATION CARE
Over the next several hours, oxygen should be weaned to maintain peripheral capillary oxygen saturation (SpO2) ≥ 92%. 
Nasal
